RxDoctor Payments Data

Colin Gillespie, MD

Pulmonary Disease · Cleveland, OHNPI 1487716437

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (34.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Boston Scientific at 37.4% of the total. Reporting peaked in 2019 at $19,017 and has fallen 82.8% since, to $3,262 in 2025. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$48,992in general payments, 2019–2025

Across 169 payments — averaging $289.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$18K
  • Intuitive Surgical$13K
  • Cook Incorporated$5K
  • Noah Medical Corporation$2K
  • Johnson & Johnson$2K
  • Pulmonx Corporation$2K
  • plus $6K from 17 others
$10,676in research payments, 2019–2025

Across 1 payment — averaging $10,676 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • BD$11K

What the payments were for

  • Consulting fees$16,90034%
  • Speaking & faculty fees$6,25013%
  • Travel & lodging$11,22823%
  • Food & beverage$8,61418%
  • Education$6,00012%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,992 in reported general payments places this provider in the 90th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio →

Medicare billing

Part B allowed, 2024
$52,398
Medicare patients
190
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,828
Prednisone15$109

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Cleveland

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →